DDInter704 DDInter156
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease, early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure.
Everolimus {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Hyperuricaemia {u} (Side Effect) is caused by {v} (Compound) Azilsartan medoxomil
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Everolimus {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Hyperuricaemia {u} (Side Effect) is caused by {v} (Compound) Candesartan
Candesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Tasosartan
Tasosartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olmesartan
Olmesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Everolimus {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Candesartan
Candesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Everolimus {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Everolimus {u} (Compound) upregulates {v} (Gene) ALAS1
ALAS1 {u} (Gene) is downregulated by {v} (Compound) Candesartan
Candesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Everolimus {u} (Compound) downregulates {v} (Gene) NUP85
NUP85 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Everolimus (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Azilsartan medoxomil (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Everolimus (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Candesartan (Compound) and Candesartan (Compound) resembles Azilsartan medoxomil (Compound)
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tasosartan (Compound) and Tasosartan (Compound) resembles Azilsartan medoxomil (Compound)
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Everolimus (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Candesartan (Compound) and Candesartan (Compound) resembles Azilsartan medoxomil (Compound)
Everolimus (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Everolimus (Compound) upregulates ALAS1 (Gene) and ALAS1 (Gene) is downregulated by Candesartan (Compound) and Candesartan (Compound) resembles Azilsartan medoxomil (Compound)
Everolimus (Compound) downregulates NUP85 (Gene) and NUP85 (Gene) is downregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil